US Patent Issued to Atea Pharmaceuticals on Feb. 17 for "Highly active compounds against COVID-19" (Massachusetts Inventors)

ALEXANDRIA, Va., Feb. 17 -- United States Patent no. 12,551,499, issued on Feb. 17, was assigned to Atea Pharmaceuticals Inc. (Boston).

"Highly active compounds against COVID-19" was invented by Jean-Pierre Sommadossi (Boston) and Adel Moussa (Burlington, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention is the use of purine nucleotide phosphoramidates or pharmaceutically acceptable salts thereof administered in an effective amount for the treatment or prevention of COVID-19, an infection caused by the SARS CoV-2 virus in a host, for example a human, in need thereof."

The patent was filed on Sept. 15, 2023, under Application No. 18/368,959.

*For further information, including image...